Analyst picks & changes

Gene therapy plays

Furman Selz analyst Bruce Schackman said gene therapy is an exciting area because there is little competition from established drug companies; and because each company is developing a drug delivery platform with a wide variety of therapeutic applications. He recommended Neozyme II Corp. (NIIUF) for investors looking for nearer-term product opportunities. He said investors with longer time horizons should consider ...